Ingrezza, a medication approved for tardive dyskinesia and chorea associated with Huntington's disease, generated $1.6 billion in net sales in 2023 [1]. This represents a significant increase from previous years, with sales reaching $969 million in 2022 and $534 million in 2021 [1].
How is Ingrezza performing quarter-over-quarter?
In the first quarter of 2024, Ingrezza reported net sales of $484 million [2]. This indicates continued growth compared to the same period in 2023 when sales were $380 million [2].
What is the commercial outlook for Ingrezza?
Analysts project strong future sales for Ingrezza. The drug has shown consistent revenue growth since its launch, and its approved indications are expanding [1][2]. The expansion into the treatment of chorea associated with Huntington's disease is expected to further contribute to its commercial success [1].
When does Ingrezza's patent protection expire?
The patent landscape for Ingrezza is complex. While specific patent expiry dates are subject to legal challenges and variations by region, information regarding drug patent expirations can be found on resources like DrugPatentWatch.com [3]. Understanding these timelines is crucial for anticipating potential generic competition.
What are the key indications for Ingrezza?
Ingrezza is FDA-approved for two primary indications: tardive dyskinesia, a neurological movement disorder characterized by involuntary, repetitive movements, and chorea associated with Huntington's disease, another neurological disorder that causes involuntary, irregular, and unpredictable movements [1].
What is the mechanism of action for Ingrezza?
Ingrezza works by selectively inhibiting vesicular monoamine transporter type 2 (VMAT2) [1]. VMAT2 is involved in the transport of monoamines, such as dopamine, within the brain. By inhibiting VMAT2, Ingrezza helps to reduce the excessive dopamine signaling that is thought to contribute to the involuntary movements seen in tardive dyskinesia and Huntington's disease chorea [1].
Are there alternative treatments for tardive dyskinesia and Huntington's disease chorea?
Other medications are available for managing tardive dyskinesia and chorea, though Ingrezza is a notable option [1]. These alternatives may include other VMAT2 inhibitors or treatments targeting different neurological pathways.
What is the pricing of Ingrezza?
Information on the specific pricing of Ingrezza can vary based on insurance coverage, pharmacy, and geographic location. Pharmaceutical companies typically do not publicly disclose exact list prices for their medications, but rather work with payers to establish reimbursement rates.
What clinical data supports Ingrezza's efficacy?
Ingrezza's approval is based on robust clinical trial data demonstrating its effectiveness in reducing the severity of involuntary movements in patients with tardive dyskinesia and Huntington's disease chorea. The trials have shown statistically significant improvements in patient-reported outcomes and clinician assessments [1].
What are the potential risks or side effects associated with Ingrezza?
As with any medication, Ingrezza carries potential risks and side effects. Common adverse events reported in clinical trials include somnolence, dry mouth, and constipation [1]. Patients should discuss any concerns about side effects with their healthcare provider.
Who manufactures Ingrezza?
Ingrezza is manufactured by Neurocrine Biosciences [1].
What is the regulatory status of Ingrezza?
Ingrezza has received approval from the U.S. Food and Drug Administration (FDA) for its indicated uses [1]. Regulatory approval signifies that the drug has met the agency's standards for safety and effectiveness.
---
Sources:
[1] https://www.neurocrine.com/news/neurocrine-biosciences-announces-fourth-quarter-and-full-year-2023-financial-results-and-provides-2024-outlook/
[2] https://www.neurocrine.com/news/neurocrine-biosciences-announces-first-quarter-2024-financial-results-and-provides-business-update/
[3] https://drugpatentwatch.com/